Edition:
United States

Sanofi SA (SASY.BE)

SASY.BE on Berlin Stock Exchange

83.60EUR
29 Mar 2017
Change (% chg)

€0.42 (+0.50%)
Prev Close
€83.18
Open
€83.60
Day's High
€83.60
Day's Low
€83.60
Volume
0
Avg. Vol
10,893
52-wk High
€83.99
52-wk Low
€67.00

SASY.BE

Chart for SASY.BE

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.90
Market Cap(Mil.): €108,452.40
Shares Outstanding(Mil.): 1,292.02
Dividend: 2.96
Yield (%): 3.53

Financials

  SASY.BE Industry Sector
P/E (TTM): 24.78 29.37 30.15
EPS (TTM): 3.39 -- --
ROI: 5.02 13.51 13.05
ROE: 7.60 14.42 14.20

Sanofi hires advisors for European generic drugs unit sale: sources

FRANKFURT/LONDON French drug maker Sanofi has hired advisers for the sale of its European generic drug business, several sources familiar with matter told Reuters, ahead of an auction process which is expected to start after the European summer.

6:58am EDT

Sanofi hires advisors for European generic drugs unit sale -sources

FRANKFURT/LONDON, March 29 French drug maker Sanofi has hired advisers for the sale of its European generic drug business, several sources familiar with matter told Reuters, ahead of an auction process which is expected to start after the European summer.

6:57am EDT

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies.

Mar 28 2017

UPDATE 3-FDA approves Regeneron, Sanofi $37,000 per year eczema drug

March 28 The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important growth driver for the two companies.

Mar 28 2017

FDA approves Regeneron, Sanofi $37,000 per year eczema drug

The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's drug for moderate-to-severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.

Mar 28 2017

BRIEF-Regeneron and Sanofi announce FDA approval of Dupixent

* Regeneron and Sanofi announce FDA approval of Dupixent® (Dupilumab), the first targeted biologic therapy for adults with moderate-to-severe atopic dermatitis

Mar 28 2017

BRIEF-U.S. list price for Sanofi, Regeneron's Dupixent $37,000

* Says U.S. list price of newly approved Dupixent atopic dermatitis drug $37,000 per patient per yearFurther company coverage: (Reporting by Ben Hirschler)

Mar 28 2017

FDA approves Regeneron, Sanofi eczema drug

March 28 The U.S. Food and Drug Administration on Tuesday approved Regeneron Pharmaceuticals Inc and Sanofi SA's Dupixent for treatment of moderate to severe atopic dermatitis, a product widely seen as the most important future growth driver for the two companies.

Mar 28 2017

BRIEF-Vivus reacquires Stendra(R)(AVANAFIL)commercial rights from Sanofi

* Reacquires Stendra(R) (Avanafil) commercial rights from Sanofi

Mar 27 2017

Doctors, patients urge court to reject ban on cholesterol drug sales

A group of doctors and patients are urging a federal appeals court to overturn a lower court order banning sales of Sanofi SA and Regeneron Pharmaceuticals Inc's cholesterol drug Praluent after Amgen Inc won a patent lawsuit against them.

Mar 23 2017

More From Around the Web

Earnings vs. Estimates